实用临床医药杂志2024，Vol.28Issue(22)：62-66,5.DOI:10.7619/jcmp.20243388
沙库巴曲缬沙坦对儿童扩张型心肌病的疗效及安全性观察
Efficacy and safety of sacubitril valsartan in treatment of dilated cardiomyopathy in children
摘要
Abstract
Objective To observe the efficacy and safety of sacubitril valsartan in the treatment of dilated cardiomyopathy(DCM)in children.Methods A total of 19 hospitalized children with DCM were retrospectively selected as study subjects.All patients received captopril combined with conventional anti-heart failure therapy for 1 to 4 weeks,but due to ineffective treatment,they were switched to treatment of sacubitril valsartan.Clinical data,biochemical indicators,and echocardio-graphic findings were collected to assess changes in clinical symptoms and related indicators after 1-,3-,6-,and 12-month sacubitril valsartan treatment.Information on the dosage and administration of sacubitril valsartan,as well as the occurrence of adverse reactions was collected.Results Among 19 patients,there were 8 males and 11 females,with a median age of 3 years.Heart function was classi-fied as grade Ⅱ in 2 patients,grade Ⅲ in 10 patients,and grade Ⅳ in 7 patients.At the final fol-low-up,the efficacy assessment showed significant improvement in 8 patients,effective improvement in 6 patients,and no improvement in 5 patients,with a total effective rate of 73.7％.After 1-,3-,6-,and 12-month sacubitril valsartan treatment,the levels of N-terminal pro-B-type natriuretic pep-tide(NT-proBNP)were lower,left ventricular ejection fraction(LVEF)was higher,and left ventricu-lar diastolic diameter(LVDd)-Z value was smaller compared with those before treatment(P＜0.05).The initial single dose of sacubitril valsartan was 0.8 mg/kg,and the average maintenance dose was 1.7 mg/kg,administered twice daily.After treatment,1 patient developed hypotension,and 5 patients exhibited mild abnormalities in renal function indicators(of which 4 recovered to normal levels after tolerance).Conclusion Sacubitril valsartan can effectively improve heart failure symptoms and cardiac function indicators in children with DCM,but close monitoring of blood pressure and renal function changes is required during treatment.关键词
沙库巴曲缬沙坦/扩张型心肌病/心力衰竭/儿童/不良反应/肾功能Key words
sacubitril valsartan/dilated cardiomyopathy/heart failure/children/adverse reactions/renal function分类
医药卫生引用本文复制引用
马丹凤,刘丽华,王野峰,李静,曾闵..沙库巴曲缬沙坦对儿童扩张型心肌病的疗效及安全性观察[J].实用临床医药杂志,2024,28(22):62-66,5.基金项目
湖南省自然科学基金项目(2023JJ30318) （2023JJ30318）
